Healthcare in Africa
Carrying a Disproportionate Share of Global Disease Burden
While 16 % of the world population live in Africa, the continent carries a disproportionate 23 % share of the global disease burden, during only 1 % of the global health expenditure and 2 % of the global doctors.
Population
60 % of the population in Africa live in rural isolated areas, and 83 % are excluded from healthcare services
Diagnosis
Low, resulting in poor outcome; As many as 80 % of cancer patients are diagnosed in late/ end stage
Affordability
High cost combined with out of pocket payments limit access to biologic treatments
Infrastructure
0.3 physicians, 1.0 nurses, 1.3 hospital beds per 1,000 people
Mission
Bringing Critical Medicines and Services to Patients
To serve the needs of patients across Africa and the Middle East (MEA region) MiGenTra created a holistic approach around our three modalities to cover all key drivers towards a better Healthcare in Africa – our TREAT strategy.
Therapies
REAch
Transformation
Products
Biologics Developed and Manufactured
In-House to Ensure Affordable Access
MiGenTra combines the extensive scientific and manufacturing expertise from both parent companies, ProBioGen and Minapharm Pharmaceuticals, for product development and commercialization in the field of three modalities.
Biosimilars
Cell and Gene Therapies (CGT)
